Vol.59 No.6 November 2011
Current status of invasive pneumococcal diseases and the preventive pneumococcal vaccines in Japan
Jpn. J. Chemother. 59 (6): 561-572, 2011
Elucidation of the calcineurin signaling pathway in pathogenic fungi to develop a novel antifungal strategy
Jpn. J. Chemother. 59 (6): 573-579, 2011
Treatment strategy aimed towards for the short-term use of linezolid in severe and refractory infections with methicillin-resistant Staphylococcus aureus
Jpn. J. Chemother. 59 (6): 580-584, 2011
Clinical response of levofloxacin 500 mg qd to urogenital infection (in compliance with the new guidelines) and examination of penetration into the prostatic tissues
Jpn. J. Chemother. 59 (6): 585-596, 2011
Dose finding study on arbekacin sulfate for appropriate peak levels
Jpn. J. Chemother. 59 (6): 597-604, 2011
The state of antimicrobial prophylaxis for transurethral resection
Jpn. J. Chemother. 59 (6): 605-609, 2011
Data mining of the public version of the FDA Adverse Event Reporting System, AERS: Colistin-associated adverse events
Jpn. J. Chemother. 59 (6): 610-613, 2011
Safety and efficacy of levofloxacin 500 mg once a day
Jpn. J. Chemother. 59 (6): 614-633, 2011